Introduction
Recent advances in the management of SJIA considered the induction or maintenance of inactive disease according to the JADAS 10-CRP (J10) or 27-CRP (J27) scoring system [1, 2] . The maintenance of efficacy of canakinumab (CAN), a selective, human, anti-IL-1β monoclonal antibody, was demonstrated in the withdrawal phase of 2 phase III trials [3], but was not evaluated at the individual level.
Objectives
To evaluate the maintenance of efficacy at the level of the individual patient from Week 2 to 12, using the adapted ACR-JIA response criteria (aACR) as well as J10 and J27 on the 12-week pooled data set (3 phase III studies).
Methods
For this post-hoc analysis of the CAN Phase III program in SJIA, the change in disease states between Day(D) 15 and D85 of a total of 178 CAN-naïve patients was assessed. Subjects were 2-19 years of age and had active SJIA at enrollment. This shift analysis considered the aACR response and certain disease activity states as defined using J10 and J27: Inactive Disease (ID), Low Disease Activity (LDA), Moderate Disease Activity (MDA); High Disease Activity (HDA).
Results
J10 changes during the study period are provided in Table 1 . Results for the J27 were very similar to the J10 observations.
The D15-D85 aACR shift analyses, including only patients who had a D15 and a D85 value, likewise indicated that the majority of patients maintained or improved their response: NR (n=32): 12.5% of patients improved; aACR30 (n=14): 0.0% were maintained/ 78.6% improved; aACR50 (n=21): 33.3% were maintained/42.9% improved; aACR70 (n=36): 25.0% were maintained/58.3% improved; aACR90 (n=26): 30.8% were maintained/57.7% improved; aACR100 (n=34): 82.4% were maintained.
Conclusion
The great majority of CAN patients either maintained or improved their JADAS status or aACR response level from week 2 to 12. These data confirm the consistent maintenance of efficacy of CAN at the individual level in the first 3 months, irrespective of the measure of response, i.e. aACR criteria or JADAS-derived criteria, and extend previous findings at the study group level. 
